Due to the inverse association of HDL-C with CHD, and the proven effect of apoA1 overexpression decreasing atherosclerosis progression in mouse models, apoA1, reconstituted HDL (rHDL), or apoA1 mimetic peptides have been utilized in multiple pre-clinical and clinical trials. The gene discussed is APOA1; the disease is coronary artery disorder.